EGFR

Cancer

Discovery of BLU-945 Brings Hope to EGFR-Positive NSCLC Patients

Mutations in the epidermal growth factor receptor (EGFR) kinase domain are the oncogenic drivers of this adenocarcinoma. Tyrosine kinase inhibitors (TKIs), developed over the last two decades, targeting EGFR mutations, […]

Osimertinib was approved for first-line treatment

Osimertinib was approved for first-line treatment

The third-generation EGFR inhibitor, Osimertinib (Tagrisso, AZD9291), was approved by the Chinese Food and Drug Administration (NMPA) recently for first-line treatment of patients with EGFR mutation-positive advanced or metastatic non-small cell lung […]

Latest treatment for non-small cell lung cancer.

Latest treatment for non-small cell lung cancer.

The prognosis of patients with early lung cancer is better, but many patients with lung cancer are diagnosed with advanced stage, and the overall five-year survival rate is only about […]

EGFR-targeted Related Drugs

EGFR-targeted Related Drugs

Introduction of EGFR EGFR is the expression product of proto-oncogene C-ERBB1, the receptor of EGF cell proliferation and signal transduction. It is a member of epidermal growth factor receptor (HER) […]

Induction of autophagic cell death by anti-cancer agent

Although the role of autophagy in cancer is very complex, various pharmacological agents with different antineoplastic properties have been shown to induce autophagic activity resulting in massive death of cells […]